Kornimate/medical-research-clean huggingface dataset:
does complement factor h gene polymorphism play a role in the regulation of vascular tone in the choroid?

Conditions: Genetic Polymorphism; Macular Degeneration; Regional Blood Flow; Ocular Physiology

Summary: age related macular degeneration (amd) is a multifactorial disease with a strong genetic component. most importantly a genetic polymorphism in the gene encoding for the complement factor h (cfh) has been recently identified which is highly associated with an increased risk of developing amd. this tyr402his polymorphism located on chromosome 1q31 has been implicated to play a role in the development of the disease. given that it is known that impaired regulation of choroidal vascular tone is present in patients with amd, the current study seeks to investigate whether the tyr402his polymorphism is associated with altered choroidal autoregulation in healthy subjects. for this purpose a total of 100 healthy volunteers will be included in order to test the hypothesis that an impaired regulation of choroidal blood flow is present in subjects with homozygous tyr402his variant.


Eligibility criteria:
inclusion criteria: * men and women aged between 18 and 35 years * nonsmokers * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * normal ophthalmic findings, ametropy less than 3 diopters exclusion criteria: * regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study * treatment in the previous 3 weeks with any drug * symptoms of a clinically relevant illness in the 3 weeks before the first study day * blood donation during the previous 3 weeks

Keywords: age-related macular degeneration complement factor h choroidal blood flow
safety and efficacy study of renal artery ablation in resistant hypertension patients

Conditions: Hypertension

Summary: this is a prospective, multicenter, feasibility study on the safety and efficacy of renal denervation in patients with resistant hypertension.

demonstrate the safety and efficacy of the st. jude medical radiofrequency (rf) renal denervation system in the treatment of patients with resistant hypertension. safety marker * all adverse events efficacy marker * office blood pressure

Eligibility criteria:
inclusion criteria: * office systolic blood pressure that remains ≥160 mmhg (≥150 mmhg for patient with type 2 diabetes) despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic, for a minimum of 14 days prior to enrollment * age ≥18 and ≤80 years old * able and willing to provide written informed consent to participate in the study * able and willing to comply with the required follow-up schedule exclusion criteria: * prior renal artery intervention (balloon angioplasty or stenting) * evidence of renal artery atherosclerosis (defined as a stenotic severity of \>30%) in either renal artery * multiple main renal arteries in either kidney * main renal arteries \<4 mm in diameter or \<20 mm in length * egfr of \<45 ml/min per 1.73 m2 using the mdrd formula * type 1 diabetes * renovascular hypertension or hypertension secondary to other renal disorders (glomerulonephritis, polycystic kidney disease, end-stage renal failure) * others

Keywords: catheter-based renal artery ablation hypertension resistant to conventional therapy
follitropin delta in long gnrh agonist and gnrh antagonist protocols (beyond)

Conditions: Infertility, Female

Summary: to compare the efficacy and safety of fe 999049 (follitropin delta) and its personalized dosing algorithm in controlled ovarian stimulation for in vitro fertilization (ivf)/intracytoplasmic sperm injection (icsi) using a long gonadotropin-releasing hormone (gnrh) agonist protocol versus a short gnrh antagonist protocol.


Eligibility criteria:
inclusion criteria: * infertile women aged 18-40 undergoing their first ivf/icsi cycle that are in good physical and mental health and that have been diagnosed with problems in the fallopian tubes, mild endometriosis or have partners with decreased sperm quality. * the participants must have a regular menstrual cycle, a normal uterus and 2 normal ovaries. * the allowed body mass index is 17.5-32 kg/m\^2. exclusion criteria: * women with very high ovarian reserve, strong preference for either treatment, severe endometriosis, history of repeated miscarriage, couples with known problems in the chromosomes, history or high risk of producing blood cloths, women known to have chronic diseases, women recently participating in trials with non-registered drugs.
study of 18f-thretide pet/ct in patients with prostate cancer

Conditions: Prostate Cancer

Summary: this study evaluates the diagnostic performance and safety of 18f-thretide pet/ct in patients with biopsy proven prostate cancer who has no any form of therapy against prostate caner or suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

prostate-specific membrane antigen (psma) is overexpressed in most cases of prostate cancer and is potentially associated with metastasis and progression of prostate cancer. compared with 68ga, the pet radionuclide 18f exhibits several advantages. 18f-thretide (18f-labeled psma ligand) has been studied for preclinical evaluation and pilot clinical study. this study evaluates the diagnostic performance and safety of 18f-thretide pet/ct in patients with with biopsy proven prostate cancer who has no any form of therapy against prostate caner or suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.

Eligibility criteria:
inclusion criteria: * male ≥ 18 years of age; * for patients with newly diagnosed prostate cancer : (1) adult patients with pca confirmed by biopsy; (2) no any form of therapy against pca within last three months; (3) planned surgical treatment; * for patients with suspected recurrence of prostate cancer: (1)histopathologically confirmed prostate adenocarcinoma per original diagnosis, with subsequent definitive therapy; (2)suspected recurrence of prostate cancer based on rising psa after definitive therapy on the basis of: post-radical prostatectomy: detectable or rising psa level ≥ 0.2 ng/ml with a confirmatory psa ≥ 0.2 ng/ml ; or post-radiation therapy, cryotherapy, or brachytherapy: increase in psa level that is elevated by ≥ 2 ng/ml above the nadir; * life expectancy ≥3 months as determined by the investigator; * able and willing to provide informed consent and comply with protocol requirements. exclusion criteria: * known allergic history to fluoride 18f-thretide injection and/or 99mtc-mdp or its excipients; * patients who cannot tolerate intravenous administration (such as a history of needle sickness or blood sickness); * those who are not suitable for or unable to complete pet or other imaging examinations due to special reasons, including claustrophobia and radiophobia, etc. * practitioners requiring prolonged exposure to radioactive conditions; * serious diseases of the heart, kidney, lung, vascular, nervous and psychiatric systems, immune deficiency diseases and hepatitis/cirrhosis; * have been diagnosed with clinical recurrence of prostate cancer; * patients receiving adt treatment or chemotherapy; * patients who participated in clinical trials of radiopharmaceuticals within the previous 1 year; * participated in other interventional clinical trials within 1 month prior to screening; * there are other conditions that the researcher considers inappropriate to participate in this study.
low back pain prevalence

Conditions: Low Back Pain; Local Stabilizers; ODI

Summary: brief summery: low back pain is a significant, serious and widespread problem in our world today, both in terms of social and economic burdens. it should be emphasized that even the young adult age group is very often affected by non-specific, low back pain without proven pathoanatomical changes. the aim of our current study is to assess the prevalence of low back pain among young adults, and we would like to examine the musculoskeletal and psychosocial factors associated with low back pain that can be justified as risk factors. our further goal is to assess and compare lumbar sensorimotor control in young people without complaints and with low back pain.


Eligibility criteria:
inclusion criteria: * in case of patients with low back pain: chronic pain * in case of asymptomatic individuals: no symptomes exclusion criteria: * serious neurologycal symptomes * serious scoliosis * previous surgery which affected the local stabilizers * serious pulmonar disease

Keywords: low back pain local stabilizers odi
comparative study for treatment of alopecia areata using carboxytherapy and intralesional steroids

Conditions: Alopecia Areata

Summary: patients with three lesions of alopecia areata are randomly recruited in this study. each lesion is randomized in to receiving either carboxytherapy in one lesion, intralesional steroids in another lesion and combination of both in the third lesion. treatment period is 3 months followed by a follow-up period of 2 months.


Eligibility criteria:
inclusion criteria: * early localized scalp alopecia areata * patients who did not receive any medication for at least 2 months before starting the study patients who agreed to join the study and signed written consent. exclusion criteria: * pregnant, and lactating females and those with unrealistic expectation. * alopecia totalis or universalis or ophiasis or cicatrising alopecia * usage of systemic treatment of alopecia areata 2 months prior to the study. * any scalp lesion within the treated area * bleeding diathesis, severe anemia or platelet disorders * medical conditions such as autoimmune diseases.
a long-term trial of eb-1020 in adult patients with adhd

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Summary: the purpose of this study is to evaluate the safety of long-term administration of mainly high doses of eb-1020 over 52 weeks in patients who have completed the double-blind trial (405-102-00112) conducted in japan


Eligibility criteria:
inclusion criteria: * participants who completed the treatment period andfollow-up period in the preceding double-blind parent trial (trial 405-102-00112) and did not meet the criteria for discontinuation of the investigational medicinal product (imp). * participants who have not been found to have major problems with trial requirements, such as compliance with the imp, in the preceding double-blind parent trial. exclusion criteria: * participants who are pregnant or breastfeeding or test positive for pregnancy on baseline visit. * participants who started prohibited concomitant medications/therapies for adhd or other comorbidities at the end of the follow-up period of the preceding trial, or participants for whom starting treatment is deemed beneficial. * participants who have a significant risk of committing suicide in the opinion of the investigator or subinvestigator, or based on the following evidence: * active suicidal ideation as evidenced by an answer of "yes" on questions 4 or 5 on the section of suicidal ideation on the since last visit version of the columbia-suicide severity rating scale (c-ssrs) in the preceding double-blind parent trial or * reported suicidal behavior * participants who were found to have serious or severe adverse events that were judged to be related to the imp in the preceding double-blind parent trial. * participants who test positive for drugs or alcohol in a urine test on baseline visit.
stereotactic body radiation therapy in treating patients with localized high-risk prostate cancer

Conditions: Adenocarcinoma of the Prostate; Stage III Prostate Cancer

Summary: this clinical trial studies stereotactic body radiation therapy in treating patients with high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the body. stereotactic body radiation therapy is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. studying quality of life in patients undergoing stereotactic body radiation therapy may help identify the long-term effects of treatment on patients with prostate cancer.

primary objectives: i. to establish the efficacy of stereotactic body radiation therapy (sbrt) in patients with high-risk localized prostate cancer compared to historical data from clinical trials. ii. to establish the safety with physician-reported outcomes after sbrt in patients with high risk localized prostate cancer. iii. to establish the quality of life with patient-reported validated questionnaires after sbrt in patients with high risk localized prostate cancer. outline: patients undergo sbrt daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician. after completion of study treatment, patients are followed up every 4 months for 1 year, every 6 months for 5 years, and then every 12 months thereafter.

Eligibility criteria:
inclusion criteria: * histologically confirmed primary non-metastatic adenocarcinoma of the prostate * risk-group classification into the dâ€™amico or national comprehensive cancer network (nccn) â€˜high-riskâ€™ group, as defined by the presence of any one of the following high-risk factors: * pre-biopsy prostate-specific antigen (psa) \>= 20 * biopsy gleason score 8-10 * clinical stage t3 * no pelvic nodal metastases (based on computed tomography \[ct\] or magnetic resonance imaging \[mri\] findings) * no distant metastases, based upon: * ct scan or mri of the pelvis within 120 days prior to registration * bone scan within 120 days prior to registration; if the bone scan is suspicious, a plain x-ray and/or mri must be obtained to rule out metastasis * karnofsky performance status (kps) \>= 70 * ability to understand, and willingness to sign, the written informed consent * patient will have opted for sbrt among definitive treatment choices exclusion criteria: * patients with any evidence of distant metastases * hormonal therapy (luteinizing hormone-releasing hormone \[lhrh\] agonist or oral anti-androgen) exceeding 4 months prior to registration * prior cryosurgery, high intensity focused ultrasound (hifu) or brachytherapy of the prostate * prior pelvic radiotherapy * history of crohnâ€™s disease or ulcerative colitis
clinical evaluation of a new cartridge for the implantation of foldable intraocular lenses

Conditions: Cataract

Summary: the aim of the study is to evaluate the safety and effectiveness of a new cartridge for the implantation of foldable intraocular lenses.

intraocular lenses (iol) cartridge is made up of polypropylene material with coating. this cartridge is used as lens delivery system for foldable lens implantation while doing cataract surgery. the coating is made up of medical grade polyurethane and biocompatible. this coating would be useful for smooth delivery of intraocular lens.

Eligibility criteria:
inclusion criteria: * age 40 to 60 * senile cataract * nuclear sclerosis grade i and grade ii exclusion criteria: * inherent zonular weakness * shallow anterior chamber * pxf * traumatic cataract * uveitis and complicated cataract * dense pscc and ppc

Keywords: cartridge iol
post marketing surveillance study of actimmune in patients with severe, malignant osteopetrosis

Conditions: Osteopetrosis

Summary: the purpose of this study is to establish a registry of all children with severe, malignant osteopetrosis who are treated with actimmune (ifn-g 1b or interferon gamma-1b) to monitor the effects of ifn-g 1b on preventing progression of this disease and to follow the safety of patients receiving it on a long-term basis. in addition, evaluation of the possible effect of actimmune therapy on the humoral response to normal childhood vaccinations in this same patient population will be examined.interferon gamma is a substance that the body makes naturally.

it is made by white blood cells and appears to be involved in regulating the body's ability to fight off infection. actimmune is a synthetic form of interferon gamma which is similar to that normally made by white blood cells. ifn-g 1b (actimmune®) is currently approved by the united states food and drug administration (fda) for the treatment of patients with chronic granulomatous disease (cgd) to reduce the frequency and severity of serious infections. it is also approved in patients with severe, malignant osteopetrosis to delay the time to disease progression. in research trials, ifn-g 1b has been given to over 2,000 patients in diseases such as cgd, osteopetrosis, atopic dermatitis, pulmonary fibrosis, atypical mycobacteria and various cancers.

Eligibility criteria:
* male or female * diagnosis of severe, malignant osteopetrosis * currently receiving or planning to initiate therapy with actimmune (interferon gamma-1b) * willing to attend follow-up appointments every 6 months following enrollment into the study, if clinically indicated

Keywords: registry actimmune osteopetrosis
multicenter retrospective observational study of relapsed diffuse large b-cell lymphoma presenting as indolent lymphoma

Conditions: Diffuse Large B Cell Lymphoma (DLBCL); Indolent B-Cell Lymphomas; Indolent B Cell Lymphoma

Summary: most relapses of diffuse large b-cell lymphoma (dlbcl) occur as high-grade lymphoma within the first two years after diagnosis. relapses as indolent lymphoma are rare events, and the true incidence of this phenomenon is unknown, since literature data are scarce/ and usually restricted to case reports. analogously, reported treatment strategies are rather heterogeneous, since no standard of care is established and advanced age together with previous anthracycline exposure may narrow the therapeutic choice. the goal of this observational study is to assess epidemiological, clinical characteristics and survival of diffuse large b-cell lymphoma (dlbcl) relapsing as indolent lymphoma. more precisely, the study aims at identifying diagnostic and imaging features associated with relapse as indolent lymphoma and at evaluating disease response to selected therapies.


Eligibility criteria:
inclusion criteria: * age 18 years or older at the time of diagnosis. * previous diagnosis of diffuse large b-cell lymphoma with/without a discordant component of indolent b-cell lymphoma, or previous diagnosis of diffuse large b-cell lymphoma transformed from indolent b-cell lymphoma. * first-line treatment for diffuse large b-cell lymphoma. * histologically documented relapse of indolent b-cell lymphoma, diagnosed between 2010 and 2020. * availability of the histological report of the relapse. * availability of clinical and laboratory data related to both the initial diagnosis and relapse. * availability of follow-up data. * consent to participate in the study and signing of the specific informed consent form (for living and/or contactable patients). exclusion criteria: - none

Keywords: indolent relapse diffuse large b cell lymphoma
pilot study of intervention to reduce sunburns in melanoma survivors

Conditions: Melanoma (Skin)

Summary: this project will pilot test whether a wearable device that tracks sun exposure and provides alerts regarding sun exposure and protection behaviors will reduce sunburns in melanoma survivors. the use of wearable technology devices has grown quickly over the last decade and studies using these devices to promote physical activity and weight loss have been promising. the investigators will pilot test the technology device versus a similar control device in 80 melanoma survivors and compare sunburns between the two groups after the three month intervention.


Eligibility criteria:
inclusion criteria: * 18-75 years old * diagnosed with stage i-iii cutaneous invasive melanoma between 2009 and 2017 and treated at the university of minnesota * able to read/write in english * own a smartphone * able to provide voluntary informed consent exclusion criteria: -patients currently undergoing adjuvant therapy.

Keywords: cancer prevention sunburn
multiparameter ultrasound based-ai for the diagnosis of thyroid nodules

Conditions: Thyroid Nodule

Summary: the cases that fulfill the inclusion criteria will be enrolled with written informed consent. images and videos will be collected in accordance with the procedure, uploaded to ruiying cloud, followed up, and registered with basic case information, such as thyroid function, fna/surgical pathology results, etc.


Eligibility criteria:
inclusion criteria: * 18\~80 years old; * thyroid nodules (acr-ti rads category 3-5，category 3 nodules ≥1cm submitted for fna) or clustered micro-calcifications; * the patients schedule to perform fna/surgery within 1 month; * without any history of invasive procedure of thyroid before (such as fna,cnb, ablation, radiation, or surgery). exclusion criteria: * incomplete data; * contraindications of ceus
fourth generation percutaneous transverse osteotomies for hallux valgus

Conditions: Hallux Valgus Deformity; Hallux Valgus (Bunion) Resection; Hallux Valgus Surgery; Hallux Deformity; Forefoot Surgery; Minimally Invasive Surgical Procedures; Minimally Invasive Surgical Technique; Hallux Abductovalgus

Summary: the goal of this observational study is to learn if percutaneous transverse osteotomies for hallux valgus deformity are safe and effective. the main questions it aims to answer are: 1. what is the change in clinical patient reported outcome measures after minimally invasive bunion surgery 2. what severity of bunion deformity can be corrected with minimally invasive surgery 3. what factors may lead to recurrence of bunion deformity 4. what is the rate of complications following bunion deformity surgery researchers will retrospectively review a research registry containing prospectively collected clinical and radiographic deformity data collected as part of routine care.


Eligibility criteria:
inclusion criteria: * primary diagnosis of hallux valgus that has failed conservative treatment exclusion criteria: * degenerative changes of first mtpj * previous hallux valgus deformity correction surgery

Keywords: bunion hallux valgus percutaneous surgery minimally invasive surgery forefoot deformity metatarsal osteotomy patient reported outcome measure manchester oxford foot questionnaire (moxfq) osteotomy observational study